Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization

BMC Musculoskeletal Disorders

Volumn 15, Issue 1, 2014, Pages

  Blanqué, Roland ^a   Lepescheux, Liên ^a   Auberval, Marielle ^a   Minet, Dominique ^a   Merciris, Didier ^a   Cottereaux, Céline ^a   Clément Lacroix, Philippe ^a   Delerive, Philippe ^a   Namour, Florence ^a  

^a Galapagos SASU   (France)

Author keywords

Anabolism; Immobilization; Muscle wasting; Selective androgen receptor modulator

Indexed keywords

GLPG 0492; RNA; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; 4-(4-(HYDROXYMETHYL)-3-METHYL-2,5-DIOXO-4-PHENYLIMIDAZOLIDIN-1-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE; ANDROGEN; ANDROGEN RECEPTOR; HYDANTOIN DERIVATIVE;

ANDROGEN THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; HINDLIMB; HOMEOSTASIS; IMMOBILIZATION; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE HYPERTROPHY; MUSCLE MASS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; TESTOSTERONE BLOOD LEVEL; ANIMAL; BAGG ALBINO MOUSE; DOSE RESPONSE; MUSCULAR ATROPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ANDROGENS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HINDLIMB SUSPENSION; HYDANTOINS; MALE; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; MUSCULAR ATROPHY; RECEPTORS, ANDROGEN;

EID: 84907060776     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-15-291     Document Type: Article

References (64)

1. Sarcopenia and aging. Kamel HK, Nutr Rev 2003 61 5 Pt 1 157 167 12822704
2. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Argiles JM, Busquets S, Felipe A, Lopez-Soriano FJ, Int J Biochem Cell Biol 2005 37 5 1084 1104 10.1016/j.biocel.2004.10.003 15743680
3. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Evans WJ, Am J Clin Nutr 2010 91 4 1123S 1127S 10.3945/ajcn.2010.28608A 20164314
4. Signaling in muscle atrophy and hypertrophy. Sandri M, Physiology (Bethesda) 2008 23 160 170 10.1152/physiol.00041.2007 18556469
5. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. Sacheck JM, Hyatt JP, Raffaello A, Jagoe RT, Roy RR, Edgerton VR, Lecker SH, Goldberg AL, Faseb J 2007 21 1 140 155 17116744
6. Identification of ubiquitin ligases required for skeletal muscle atrophy. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ, Science 2001 294 5547 1704 1708 10.1126/science.1065874 11679633
7. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL, Proc Natl Acad Sci U S A 2001 98 25 14440 14445 10.1073/pnas.251541198 11717410
8. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL, Cell 2004 117 3 399 412 10.1016/S0092-8674(04)00400-3 15109499
9. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E, Rakhilin SV, Stitt TN, Patterson C, Latres E, Glass DJ, Cell Metab 2007 6 5 376 385 10.1016/j.cmet.2007.09.009 17983583
10. Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. Fielitz J, Kim MS, Shelton JM, Latif S, Spencer JA, Glass DJ, Richardson JA, Bassel-Duby R, Olson EN, J Clin Invest 2007 117 9 2486 2495 10.1172/JCI32827 17786241
11. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ, Patterson C, J Clin Invest 2004 114 8 1058 1071 10.1172/JCI200422220 15489953
12. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, Leibovitch SA, J Biol Chem 2005 280 4 2847 2856 10.1074/jbc.M411346200 15531760
13. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y, Mol Biol Cell 2004 15 3 1101 1111 14699058
14. Leucine limitation induces autophagy and activation of lysosome-dependent proteolysis in C2C12 myotubes through a mammalian target of rapamycin-independent signaling pathway. Mordier S, Deval C, Bechet D, Tassa A, Ferrara M, J Biol Chem 2000 275 38 29900 29906 10.1074/jbc.M003633200 10893413
15. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T, Mochida K, Hata T, Matsuda J, Aburatani H, Nishino I, Ezaki O, J Biol Chem 2004 279 39 41114 41123 10.1074/jbc.M400674200 15272020
16. FOXO1 regulates the expression of 4E-BP1 and inhibits mTOR signaling in mammalian skeletal muscle. Southgate RJ, Neill B, Prelovsek O, El-Osta A, Kamei Y, Miura S, Ezaki O, McLoughlin TJ, Zhang W, Unterman TG, Febbraio MA, J Biol Chem 2007 282 29 21176 21186 10.1074/jbc.M702039200 17510058
17. Limb immobilization induces a coordinate down-regulation of mitochondrial and other metabolic pathways in men and women. Abadi A, Glover EI, Isfort RJ, Raha S, Safdar A, Yasuda N, Kaczor JJ, Melov S, Hubbard A, Qu X, Phillips SM, Tarnopolsky M, PLoS One 2009 4 8 6518 10.1371/journal.pone.0006518 19654872
18. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-Duby R, Spiegelman BM, Nature 2002 418 6899 797 801 10.1038/nature00904 12181572
19. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL, Spiegelman BM, Proc Natl Acad Sci U S A 2006 103 44 16260 16265 10.1073/pnas.0607795103 17053067
20. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R, N Engl J Med 1996 335 1 1 7 10.1056/NEJM199607043350101 8637535
21. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S, J Clin Endocrinol Metab 2003 88 4 1478 1485 10.1210/jc.2002-021231 12679426
22. The steroid and thyroid hormone receptor superfamily. Evans RM, Science 1988 240 4854 889 895 10.1126/science.3283939 3283939
23. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, Dalton JT, Mol Endocrinol 2008 22 11 2448 2465 10.1210/me.2008-0160 18801930
24. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT, Nat Clin Pract Endocrinol Metab 2006 2 3 146 159 10.1038/ncpendmet0120 16932274
25. Selective androgen receptor modulators in preclinical and clinical development. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT, Nucl Recept Signal 2008 6 010 19079612
26. Identification of a 4-(hydroxymethyl) diarylhydantoin as a selective androgen receptor modulator. Nique F, Hebbe S, Triballeau N, Peixoto C, Lefrançois JM, Jary H, Alvey L, Manioc M, Housseman C, Klaassen H, Van Beeck K, Guédin D, Namour F, Minet D, Van der Aar E, Feyen J, Fletcher S, Blanqué R, Robin-Jagerschmidt C, Deprez P, Journal of medicinal chemistry 2012 55 19 8236 8247 10.1021/jm300281x 22957947
27. Discovery of diarylhydantoins as new selective androgen receptor modulators. Nique F, Hebbe S, Peixoto C, Annoot D, Lefrançois JM, Duval E, Michoux L, Triballeau N, Lemoullec JM, Mollat P, Thauvin M, Prangé T, Minet D, Clément-Lacroix P, Robin-Jagerschmidt C, Fleury D, Guédin D, Deprez P, J Med Chem 2012 55 19 8225 8235 10.1021/jm300249m 22897611
28. Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles. Okamoto T, Torii S, Machida S, J Physiol Sci 2011 61 6 537 546 10.1007/s12576-011-0175-6 21901639
29. Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription. Delerive P, Galardi CM, Bisi JE, Nicodeme E, Goodwin B, Mol Endocrinol 2004 18 10 2378 2387 10.1210/me.2004-0132 15218078
30. A PGC-1 isoform induced by resistance training regulates skeletal muscle hypertrophy. Ruas JL, White JP, Rao RR, Kleiner S, Brannan KT, Harrison BC, Greene NP, Wu J, Estall JL, Irving BA, Lanza IR, Rasbach KA, Okutsu M, Nair KS, Yan Z, Leinwand LA, Spiegelman BM, Cell 2012 151 6 1319 1331 10.1016/j.cell.2012.10.050 23217713
31. The denervated muscle: facts and hypotheses. A historical review. Midrio M, Eur J Appl Physiol 2006 98 1 1 21 10.1007/s00421-006-0256-z 16896733
32. Hindlimb unloading rodent model: technical aspects. Morey-Holton ER, Globus RK, J Appl Physiol 2002 92 4 1367 1377 11895999
33. A model of muscle atrophy using cast immobilization in mice. Frimel TN, Kapadia F, Gaidosh GS, Li Y, Walter GA, Vandenborne K, Muscle Nerve 2005 32 5 672 674 10.1002/mus.20399 16025524
34. Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Jones A, Hwang DJ, Narayanan R, Miller DD, Dalton JT, Endocrinology 2010 151 8 3706 3719 10.1210/en.2010-0150 20534726
35. Testosterone protects against dexamethasone-induced muscle atrophy, protein degradation and MAFbx upregulation. Zhao W, Pan J, Zhao Z, Wu Y, Bauman WA, Cardozo CP, J Steroid Biochem Mol Biol 2008 110 1-2 125 129 18436443
36. The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice. Caron AZ, Haroun S, Leblanc E, Trensz F, Guindi C, Amrani A, Grenier G, BMC Musculoskelet Disord 2011 12 185 10.1186/1471-2474-12-185 21843349
37. Changes in signalling molecule levels in 10-day hindlimb immobilized rat muscles. Machida S, Booth FW, Acta Physiol Scand 2005 183 2 171 179 10.1111/j.1365-201X.2004.01395.x 15676058
38. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, Storer TW, Casaburi R, Shen R, Bhasin S, Am J Physiol Endocrinol Metab 2002 283 1 154 E164 12067856
39. A novel hindlimb immobilization procedure for studying skeletal muscle atrophy and recovery in mouse. Caron AZ, Drouin G, Desrosiers J, Trensz F, Grenier G, J Appl Physiol 2009 106 6 2049 2059 10.1152/japplphysiol.91505.2008 19342435
40. Analysis of human skeletal muscle after 48 h immobilization reveals alterations in mRNA and protein for extracellular matrix components. Urso ML, Scrimgeour AG, Chen YW, Thompson PD, Clarkson PM, J Appl Physiol 2006 101 4 1136 1148 10.1152/japplphysiol.00180.2006 16763108
41. Nerve activity-independent regulation of skeletal muscle atrophy: role of MyoD and myogenin in satellite cells and myonuclei. Hyatt JP, Roy RR, Baldwin KM, Edgerton VR, Am J Physiol Cell Physiol 2003 285 5 1161 C1173 10.1152/ajpcell.00128.2003 12839833
42. The role of cytokines in cancer cachexia. Argiles JM, Lopez-Soriano FJ, Med Res Rev 1999 19 3 223 24843 10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N 10232651
43. Gene expression-based screening identifies microtubule inhibitors as inducers of PGC-1alpha and oxidative phosphorylation. Arany Z, Wagner BK, Ma Y, Chinsomboon J, Laznik D, Spiegelman BM, Proc Natl Acad Sci U S A 2008 105 12 4721 4726 10.1073/pnas.0800979105 18347329
44. Early change in skeletal muscle protein synthesis after limb immobilization of rats. Booth FW, Seider MJ, J Appl Physiol 1979 47 974 977 511723
45. Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. Busquets S, Alvarez B, Llovera M, Agell N, Lopez-Soriano FJ, Argiles JM, J Cell Physiol 2000 184 3 380 384 10.1002/1097-4652(200009)184:3<380::AID-JCP13>3.0.CO;2-F 10911370
46. Modulations of muscle protein metabolism by branched-chain amino acids in normal and muscle-atrophying rats. Kobayashi H, Kato H, Hirabayashi Y, Murakami H, Suzuki H, J Nutr 2006 136 1 Suppl 234S 236S 16365089
47. Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by tumor necrosis factor-alpha. Bonetto A, Penna F, Minero VG, Reffo P, Costamagna D, Bonelli G, Baccino FM, Costelli P, Amino Acids 2011 40 2 585 594 10.1007/s00726-010-0683-3 20623149
48. Branched-chain amino acids reduce hindlimb suspension-induced muscle atrophy and protein levels of atrogin-1 and MuRF1 in rats. Maki T, Yamamoto D, Nakanishi S, Iida K, Iguchi G, Takahashi Y, Kaji H, Chihara K, Okimura Y, Nutr Res 2012 32 9 676 683 10.1016/j.nutres.2012.07.005 23084640
49. Comparison of the anticatabolic effects of leucine and Ca-β-hydroxy-β-methylbutyrate in experimental models of cancer cachexia. Mirza KA, Pereira SL, Voss AC, Tisdale MJ, Nutrition 2014 30 7-8 807 813 24984997
50. Metabolic signatures of exercise in human plasma. Lewis GD, Farrell L, Wood MJ, Martinovic M, Arany Z, Rowe GC, Souza A, Cheng S, McCabe EL, Yang E, Shi X, Deo R, Roth FP, Asnani A, Rhee EP, Systrom DM, Semigran MJ, Vasan RS, Carr SA, Wang TJ, Sabatine MS, Clish CB, Gerszten RE, Sci Transl Med 2010 2 33 33ra37 20505214
51. Oxandrolone enhances hepatic ketogenesis in adult men. Vega GL, Clarenbach JJ, Dunn F, Grundy SM, J Investig Med 2008 56 7 920 924 18797410
52. Medium chain acylcarnitines dominate the metabolite pattern in humans under moderate intensity exercise and support lipid oxidation. Lehmann R, Zhao X, Weigert C, Simon P, Fehrenbach E, Fritsche J, Machann J, Schick F, Wang J, Hoene M, Schleicher ED, Häring HU, Xu G, Niess AM, PLoS One 2010 5 7 11519 10.1371/journal.pone.0011519 20634953
53. The Safety, Pharmacokinetics, and Effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, Ulloor J, Zhang A, Eder R, Zientek H, Gordon G, Kazmi S, Sheffield-Moore M, Bhasin S, J Gerontol A Biol Sci Med Sci 2013 68 1 87 95 10.1093/gerona/gls078 22459616
54. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS, J Cachexia Sarcopenia Muscle 2011 2 3 153 161 10.1007/s13539-011-0034-6 22031847
55. Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions. Dubois V, Laurent M, Boonen S, Vanderschueren D, Claessens F, Cell Mol Life Sci 2011 69 10 1651 1667 22101547
56. Myocytic androgen receptor controls the strength but not the mass of limb muscles. Chambon C, Duteil D, Vignaud A, Ferry A, Messaddeq N, Malivindi R, Kato S, Chambon P, Metzger D, Proc Natl Acad Sci U S A 2010 107 32 14327 14332 10.1073/pnas.1009536107 20660752
57. Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice. MacLean HE, Chiu WS, Notini AJ, Axell AM, Davey RA, McManus JF, Ma C, Plant DR, Lynch GS, Zajac JD, Faseb J 2008 22 8 2676 2689 10.1096/fj.08-105726 18390925
58. Ornithine decarboxylase is upregulated by the androgen receptor in skeletal muscle and regulates myoblast proliferation. Lee NK, Skinner JP, Zajac JD, MacLean HE, Am J Physiol Endocrinol Metab 2011 301 1 172 E179 10.1152/ajpendo.00094.2011 21505150
59. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE, Cell 2004 119 2 285 298 10.1016/j.cell.2004.09.027 15479644
60. Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. Hunter RB, Kandarian SC, J Clin Invest 2004 114 10 1504 1511 10.1172/JCI200421696 15546001
61. Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. Hunter RB, Stevenson E, Koncarevic A, Mitchell-Felton H, Essig DA, Kandarian SC, Faseb J 2002 16 6 529 538 10.1096/fj.01-0866com 11919155
62. Interleukin 1 and tumor necrosis factor do not regulate protein balance in skeletal muscle. Moldawer LL, Svaninger G, Gelin J, Lundholm KG, Am J Physiol 1987 253 6 Pt 1 766 C773 3501247
63. Alterations of protein turnover underlying disuse atrophy in human skeletal muscle. Phillips SM, Glover EI, Rennie MJ, J Appl Physiol (1985) 2009 107 3 645 654 10.1152/japplphysiol.00452.2009 19608931
64. Little change in markers of protein breakdown and oxidative stress in humans in immobilization-induced skeletal muscle atrophy. Glover EI, Yasuda N, Tarnopolsky MA, Abadi A, Phillips SM, Appl Physiol Nutr Metab 2010 35 2 125 133 10.1139/H09-137 20383222